NCT05493566 2026-02-12Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerEmory UniversityPhase EARLY_PHASE1 Recruiting15 enrolled
NCT03574220 2020-04-07Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung CancerCase Comprehensive Cancer CenterPhase EARLY_PHASE1 Withdrawn